StockData
Alumis Inc. logo

Alumis Inc. (ALMS) stock

ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$5.14−0.46 (-8.21%)

Close on Nov 16, 2026Market cap $665.30MP/E –Yield –

Alumis r&d expenses

Research and development expenses are spending on new products and technology.

Alumis's R&D Expenses for the twelve months ending Jun 30, 2026 was $347.50M, down 8.7% year over year. For fiscal 2025 it was $386.00M, up 45.4% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$386.00M+45.4%
FY2024Dec 31, 2024$265.55M+92.9%
FY2023Dec 31, 2023$137.68M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$85.34M-21.5%
Q1 FY2026Mar 31, 2026$81.54M-15.6%
Q4 FY2025Dec 31, 2025$82.79M-5.1%
Q3 FY2025Sep 30, 2025$97.84M+11.4%
Q2 FY2025Jun 30, 2025$108.76M+123.9%
Q1 FY2025Mar 31, 2025$96.62M+130.3%
Q4 FY2024Dec 31, 2024$87.20M+152.0%
Q3 FY2024Sep 30, 2024$87.82M+132.4%
Q2 FY2024Jun 30, 2024$48.57M+47.8%
Q1 FY2024Mar 31, 2024$41.96M–
Q4 FY2023Dec 31, 2023$34.61M–
Q3 FY2023Sep 30, 2023$37.79M–
Q2 FY2023Jun 30, 2023$32.85M–

More Alumis figures

See a number that looks wrong?